Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 5/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493305 | 0.85 | MAPT (0.41) | MAPTMEN1KMT2AALKBH5FTO | |
| SCHEMBL1493281 | 0.85 | BRAF (0.40) | MAPTMEN1KMT2AALKBH5RECQL | |
| SCHEMBL1490944 | 0.84 | MAPT (0.38) | MAPTMEN1KMT2AALKBH5RECQL | |
| SCHEMBL1491001 | 0.80 | MAPT (0.40) | MAPTALKBH5RECQLTDP1FTO | |
| SCHEMBL1490967 | 0.79 | MAPT (0.38) | MAPTMEN1KMT2AALKBH5RECQL | |
| SCHEMBL1493314 | 0.77 | MAPT (0.63) | MAPTALKBH5FTOPOLBCYP1A2 | |
| SCHEMBL1493336 | 0.75 | ALKBH5 (0.61) | MAPTMEN1KMT2AALKBH5FTO | |
| SCHEMBL1493317 | 0.74 | LMNA (0.40) | MEN1KMT2ARECQLCYP1A2LMNA | |
| SCHEMBL1493319 | 0.72 | MAPT (0.55) | MAPTMEN1KMT2ATDP1POLB | |
| SCHEMBL1493335 | 0.72 | MAPT (0.45) | MAPTALKBH5FTOCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPT 900/4885MEN1 575/4885KMT2A 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.